DRUGapprovedsmall molecule
Haloperidol
Brand names: Haldol, Serenace
Mechanism
D2 dopamine antagonist - SMA repurposed via Menduti 2026.
Approved indications
schizophreniaacute psychosisTourette syndrome
Structure
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
Related claims (2)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| drug efficacy | Haloperidol, or a pharmaceutically acceptable salt, ester or solvate thereof, is for use in a method for preventing and/or treating spinal muscular atrophy. | 53% | EP4387622B1 |
| drug efficacy | Haloperidol may be used for treating spinal muscular atrophy (clinical trial result) | 50% | ES3034601T3 |
Off-Target Findings (25)
T1: 5T4: 11untiered: 9
| Target | Role | Tier | Boltz-2 iPTM | Chai-1 iPTM | Verdict |
|---|---|---|---|---|---|
| NCALD | SMA | T1 | 0.796 | — | Primary SMA hit |
| GAP43 | SMA | T1 | 0.765 | — | Primary SMA hit |
| SMN2 | SMA | T1 | 0.763 | — | Primary SMA hit |
| ROCK2 | SMA | T1 | 0.706 | — | Primary SMA hit |
| CFL1 | SMA | T1 | 0.570 | — | Primary SMA hit |
| SMN1_YGbox | OTHER | T4 | 0.939 | — | Low relevance |
| PLS3_EF4 | OTHER | T4 | 0.888 | — | Low relevance |
| LIMK2_aC | OTHER | T4 | 0.775 | — | Low relevance |
| RAPSN_nterm | OTHER | T4 | 0.774 | — | Low relevance |
| CHRNA1_ECD | OTHER | T4 | 0.772 | — | Low relevance |
| HSP70_NBD | OTHER | T4 | 0.768 | — | Low relevance |
| ROCK2_aC | OTHER | T4 | 0.729 | — | Low relevance |
| LRP4_propeller | OTHER | T4 | 0.727 | — | Low relevance |
| ROCK1_aC | OTHER | T4 | 0.704 | — | Low relevance |
| DRD2 | OTHER | T4 | 0.582 | — | Low relevance |
| KCNA2_pore | OTHER | T4 | 0.554 | — | Low relevance |
| PFN2 | SMA | — | 0.871 | — | — |
| STMN1 | SMA | — | 0.768 | — | — |
| CHRNG_fetal | OTHER | — | 0.735 | — | — |
| PERP_ECL1 | OTHER | — | 0.637 | — | — |
| CFL2 | SMA | — | 0.551 | — | — |
| SSH1_phosphatase | OTHER | — | 0.475 | — | — |
| DOK7_PH | OTHER | — | 0.445 | — | — |
| PERP | SMA | — | 0.398 | — | — |
| KCNA2 | SMA | — | 0.358 | — | — |